Fundraising FoxAdverum Biotechnologies
Redwood City, US · 6 known investors
Find your way into Adverum Biotechnologies
Sign up to see every warm intro you have to Adverum Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adverum Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.
Founders & leadership
Board
Investors · 6
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · funding news · glance.eyesoneyecare.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · glance.eyesoneyecare.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$192.9M disclosed across 3 of 4 rounds · 2014–2024
▶$127.8MraisedFeb 2024 · 20 investors · BiotechnologyRule 506(b)
- C. David NicholsonDirector
- Linda RubinsteinExecutive Officer
- Rabia Gurses OzdenDirector
- Setareh SeyedkazemiExecutive Officer
- Kishor Peter SoparkarExecutive Officer
- Soo HongDirector
- Dawn SvoronosDirector
- James ScopaDirector
- Reed TucksonDirector
- Mark LupherDirector
- Laurent FischerExecutive Officer, Director
- Patrick MachadoDirector
- Scott WhitcupDirector
- Offering amount
- $127.8M
- Amount sold
- $127.8M
- Sales commissions
- $7.7M
- Placement agents
- Cowen and Company, LLC, Truist Securities, Inc.
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedSep 2014 · 1 investors · BiotechnologyRule 506(b)
- Linda BainExecutive Officer
- Paul WachterDirector
- Mehdi GasmiExecutive Officer
- Mark BlumenkranzDirector
- John McLaughlinDirector
- Hans HullExecutive Officer
- Thomas ChalbergExecutive Officer, Director
- Steven SchwartzDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55.1MraisedApr 2014 · 45 investors · BiotechnologyRule 506(b)
- Thomas W. ChalbergExecutive Officer, Director
- John McLaughlinDirector
- Steven D. SchwartzDirector
- Paul WachterDirector
- Mark S. BlumenkranzDirector
- Offering amount
- $56M
- Amount sold
- $55.1M
- Sales commissions
- $2.5M
- Placement agents
- Cowen and Company, LLC
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Adverum Biotechnologies do?
- Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.
- Who founded Adverum Biotechnologies?
- Adverum Biotechnologies was founded by Thomas W. Chalberg, Steven D. Schwartz, Mark S. Blumenkranz.
- Who are Adverum Biotechnologies's investors?
- Adverum Biotechnologies's investors include Avoro Capital Advisors, Frazier Life Sciences, 5AM Ventures, Samsara BioCapital, Venrock Healthcare Capital Partners, Vivo Capital.
- How much funding has Adverum Biotechnologies raised?
- Adverum Biotechnologies has disclosed $192.9M raised across 3 of its 4 known rounds.
- Where is Adverum Biotechnologies headquartered?
- Adverum Biotechnologies is headquartered in Redwood City, US.